AAN 2023 | Unmet needs in acute migraine treatment

Timothy Smith, MD, RPh, FACP, StudyMetrix Research, St. Louis, MO, discusses unmet needs in acute migraine treatment. Despite the development of new therapies in recent years, patients may face access problems. Additionally, most migraine treatments are oral medications, which poses an issue for patients who suffer from nausea or struggle to absorb oral medications. It is, therefore, essential to develop alternative therapies for these patients. There have been recent advancements in CGRP treatments, monoclonal antibodies, and small molecular weight therapeutics that can be administered as a nasal spray, providing an alternative route of treatment for these patients. Current research is also exploring the use of neuromodulation devices and neurotoxin therapies. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.